Scholars@Duke publication: A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy

A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy

Publication , Journal Article

Rein, L; Rizzieri, DA

Published in: Transplantation and Cellular Therapy

March 2021

Published version (DOI) Publisher Link

Duke Scholars

Author Lindsay Anne Magura Rein Medicine, Hematologic Malignancies and Cellular Therapy

Published In

Transplantation and Cellular Therapy

DOI

10.1016/s2666-6367(21)00198-6

ISSN

2666-6367

Publication Date

March 2021

Volume

27

Issue

3

Start / End Page

S161 / S161

Publisher

Elsevier BV

Citation

APA

Chicago

ICMJE

MLA

NLM

Rein, L., & Rizzieri, D. A. (2021). A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy, 27(3), S161–S161. https://doi.org/10.1016/s2666-6367(21)00198-6

Rein, Lindsay, and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Transplantation and Cellular Therapy 27, no. 3 (March 2021): S161–S161. https://doi.org/10.1016/s2666-6367(21)00198-6.

Rein L, Rizzieri DA. A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy. 2021 Mar;27(3):S161–S161.

Rein, Lindsay, and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Transplantation and Cellular Therapy, vol. 27, no. 3, Elsevier BV, Mar. 2021, pp. S161–S161. Crossref, doi:10.1016/s2666-6367(21)00198-6.

Rein L, Rizzieri DA. A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy. Elsevier BV; 2021 Mar;27(3):S161–S161.

Published In

Transplantation and Cellular Therapy

DOI

10.1016/s2666-6367(21)00198-6

ISSN

2666-6367

Publication Date

March 2021

Volume

27

Issue

3

Start / End Page

S161 / S161

Publisher

Elsevier BV